The HSPB8 Knockout HT29 Polyclonal Cells comprise a polyclonal population of HT29 cells subjected to CRISPR/Cas9-mediated gene disruption targeting the HSPB8 locus. This polyclonal knockout pool provides a heterogeneous model carrying a spectrum of HSPB8 loss-of-function alleles, enabling robust investigation of HSPB8-dependent phenotypes without clonal selection bias. The cells are delivered as a ready-to-use edited population, suitable for direct expansion or cryopreservation, and validated to confirm efficient disruption of HSPB8 expression at the protein or mRNA level.
The HT29 host line is an established human colorectal adenocarcinoma cell line originally isolated from a primary tumor of a female patient. These cells display an epithelial morphology and are widely employed as a model system for colorectal cancer biology, including studies of tumor cell signaling, differentiation, drug resistance, and metastasis. Their well-characterized genetic background, including common mutations in APC, TP53, and KRAS pathways, makes them particularly valuable for dissecting oncogenic mechanisms and therapeutic vulnerabilities.
HSPB8 (heat shock protein beta-8) is a small heat shock protein exhibiting chaperone activity critical for proteostasis. Under stress conditions such as heat shock or oxidative challenge, HSPB8 is transcriptionally induced by HSF1, estrogen receptor, and p53. It orchestrates chaperone-assisted selective autophagy (CASA) by recruiting the BAG3-HSC70-CHIP (STUB1) complex to ubiquitinated misfolded proteins, targeting them for lysosomal degradation. This mechanism suppresses apoptosis, partly by maintaining anti-apoptotic proteins BCL-2 and BCL-xL. HSPB8 also interacts with HSPB1 and influences MAPK/ERK and Akt signaling, thereby integrating stress responses with cell survival decisions.
In HT29 colorectal carcinoma cells, HSPB8 likely supports proteostasis amid elevated oxidative and metabolic stress typical of the tumor milieu. Disruption of HSPB8 may impair CASA, causing accumulation of protein aggregates, increased sensitivity to apoptosis, and reduced viability under chemotherapeutic stress. Thus, this polyclonal knockout model enables dissection of colorectal cancer dependence on autophagy-mediated quality control and evaluation of HSPB8 as a therapeutic target, while also facilitating exploration of autophagy-apoptosis crosstalk in an epithelial cancer context.
Key applications include monitoring autophagic flux via LC3 and p62 immunoblotting or fluorescent reporters, apoptosis assays (Annexin V/PI, caspase-3 cleavage), and cell viability studies under stress. The cells are suitable for compound screening and phospho-signaling analysis of Akt and ERK pathways. Researchers can validate HSPB8 knockout by RT-qPCR or immunofluorescence. The polyclonal nature captures population-level heterogeneity. For detailed protocols, technical support, or custom gene-editing services, please contact Ascent Research.
